NetworkNewsBreaks

WednesdayFeb 08, 2023 11:17 am

NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate in a question-and-answer session. Interested parties should visit https://nnw.fm/QT5Tu to register for the webinar. To view the full press release, visit https://nnw.fm/VRcvC About India Globalization Capital Inc. IGC develops advanced cannabinoid-based formulations for treating diseases…

Continue Reading

WednesdayFeb 08, 2023 10:56 am

NetworkNewsBreaks — DoubleDown Interactive Co. Ltd. (NASDAQ: DDI) Releases Q4, FY2022 Financial Report

DoubleDown Interactive (NASDAQ: DDI), a leading gaming company delivering unique player experiences across a variety of genres, is reporting its unaudited financial results for the fourth quarter and year ended Dec. 31, 2022. Highlights of the Q4 report show that revenue for the company decreased from $86.3 million in the fourth quarter of 2021 to $76.2 million in the fourth quarter of 2022 while operating costs for the same period increased to $321.4 million.  The company also noted that Adjusted EBITDA decreased to $24.7 million for Q4 2023 and that overall, DDI saw a net loss of $194.4 million. Full-year numbers…

Continue Reading

TuesdayFeb 07, 2023 3:45 pm

NetworkNewsBreaks – Selina Hospitality PLC. (NASDAQ: SLNA) Publishes New Investor Presentation

Selina Hospitality (NASDAQ: SLNA), the fast-growing experiential hospitality brand targeting millennial and Gen Z travelers, recently announced the release of a new investor presentation. The presentation includes summary information about the company and new and updated details regarding Selina’s comprehensive strategy, potential financing initiatives Selina is considering, as well as an overview of recent performance optimization and cost control initiatives and operational improvements. The presentation is accessible under the “Events and Presentations” section of Selina’s website. To view the full press release, visit https://nnw.fm/Cr7Gf About Selina Hospitality PLC Selina is one of the world's largest hospitality brands built to address…

Continue Reading

TuesdayFeb 07, 2023 2:51 pm

NetworkNewsBreaks – IBN to Heighten Outreach for Winter Wonderland Best Ideas Virtual Conference

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced that it is collaborating with The MicroCap Rodeo for the Winter Wonderland Best Ideas Conference. The event is slated to take place in a virtual format on Feb. 21-24, 2023. Curated in an environment primed for business efficiency and to cement long-term collaboration, Winter Wonderland will facilitate meaningful conversations between senior management of exciting microcap and small cap companies and qualified institutional investors. “The first two editions of this conference proved to be a great success. IBN is honored to work alongside their experienced team and connect our…

Continue Reading

TuesdayFeb 07, 2023 1:54 pm

NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar and chronic pain,” a recent article reads. “In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a…

Continue Reading

TuesdayFeb 07, 2023 1:39 pm

NetworkNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Epitomizing Potential Success with Focus on Less Traditional Mining Jurisdictions

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, boasts one of the most potentially significant silver and tin deposits within the Cerro Rico region and has recently looked to expand its addressable deposit through the acquisition of the adjoining Mina Casiterita and Mina Hoyada properties. “Marc Bristow, the CEO of Barrick Gold Corp, told investors during his keynote speech at the Mines & Money London conference that the future of mining no longer lay in the traditional, over-explored jurisdictions of prior…

Continue Reading

TuesdayFeb 07, 2023 1:24 pm

NetworkNewsBreaks — Advisors Mortgage Group Hosts NJHMFA Presentation for Loan Officers, Processing and Underwriting Teams

Advisors Mortgage Group, based in Ocean Township, New Jersey, held a New Jersey Housing and Mortgage Finance Agency (“NJHMFA”) info session this week. The Feb. 2 event was held at branches in West Long Branch, New Jersey, and featured several NJHMFA representatives; the reps spoke to Advisors’ loan officers and processing and underwriting teams about the loan programs that the agency offers. According to the announcement, NJHMFA is a state government agency working to improve the quality of life for residents and communities throughout New Jersey; the agency accomplishes this by investing in, financing and facilitating access to affordable rental…

Continue Reading

TuesdayFeb 07, 2023 1:20 pm

NetworkNewsBreaks – AERWINS Technology Inc. (NASDAQ: AWIN) Completes Business Combination with PONO Capital Corp.

AERWINS (NASDAQ: AWIN), the developer and manufacturer of air mobility platform, C.O.S.M.O.S. (Centralized Operating System for Managing Open Sky), and the XTURISMO Limited Edition Hoverbike, recently announced the closing of its business combination with Pono Capital Corp., a special purpose acquisition company, pursuant to the merger agreement between the parties. According to the update, the company closed the merger agreement with Pono Capital and its wholly owned subsidiary, Pono Merger Sub Inc., and AERWINS Inc., a Japanese company previously named AERWINS Technologies Inc. At the closing, Pono Merger Sub Inc. merged with and into AERWINS Inc., with AERWINS Inc. surviving…

Continue Reading

TuesdayFeb 07, 2023 12:19 pm

NetworkNewsBreaks – Utopia VR President Featured in Latest Episode of Bell2Bell Podcast

Utopia VR, one of the world’s first metaverse-as-a-service solutions for business, is featured in the most recent release from The Bell2Bell Podcast. During the interview, Utopia VR president Stuart Gray and Bell2Bell host Jonathan Keim discuss how the VR space has evolved and Utopia VR’s entry into the space. In addition, Gray provided a tour of one of Utopia VR’s 3D environments designed to help professionals collaborate and socialize. Gray also outlined the company’s business-focused strategy, explained how Utopia VR is integrating artificial intelligence (“AI”) into its platform and shared his vision for the future of the metaverse. The Bell2Bell…

Continue Reading

TuesdayFeb 07, 2023 12:14 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward with its proposed phase 1 clinical trial in Canada. The notification came in the form of a No Objection Letter (“NOL”) from Health Canada. The letter gives FSD Pharma regulatory approval to proceed with its clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of multiple sclerosis. The first-in-human clinical trial is designed to evaluate the safety…

Continue Reading